Literature DB >> 34297215

Decisions of persons, the pharmaceutical industry, and donors in disease contraction and recovery assuming virus mutation.

Kjell Hausken1, Mthuli Ncube2.   

Abstract

BACKGROUND: The article develops an eight-period game between N persons and a pharmaceutical company. The choices of a donor and Nature are parametric.
METHODS: Persons choose between safe and risky behavior, and whether or not to buy drugs. The pharmaceutical company chooses whether or not to develop drugs. The donor chooses parametrically whether to subsidize drug purchases and drug developments. Nature chooses disease contraction, recovery, death, and virus mutation. The game is solved with backward induction.
RESULTS: The conditions are specified for each of seven outcomes ranging from safe behavior to risky behavior and buying no or one or both drugs. The seven outcomes distribute themselves across three outcomes for the pharmaceutical company, which are to develop no drugs, develop one drug, and develop two drugs if the virus mutates. For these three outcomes the donor's expected utility is specified.
CONCLUSION: HIV/AIDS data is used to present a procedure for parameter estimation. The players' strategic choices are exemplified. The article shows how strategic interaction between persons and a pharmaceutical company, with parametric choices of a donor and Nature, impact whether persons choose risky or safe behavior, whether a pharmaceutical company develops no drugs or one drug, or two drugs if a virus mutates, and the impact of subsidies by a donor.
© 2021. The Author(s).

Entities:  

Keywords:  Death; Disease contraction; Donors; Drug development; Game theory; Health; Patients; Pharmaceutical industry; Recovery; Safe versus risky behavior; Subsidies; Virus mutation

Year:  2021        PMID: 34297215     DOI: 10.1186/s13561-021-00320-4

Source DB:  PubMed          Journal:  Health Econ Rev        ISSN: 2191-1991


  16 in total

1.  HIV/AIDS prevention and treatment.

Authors:  Gregg Gonsalves
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321

2.  The economics of HIV/AIDS in low-income countries: the case for prevention.

Authors:  David Canning
Journal:  J Econ Perspect       Date:  2006

3.  Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire.

Authors:  Sue J Goldie; Yazdan Yazdanpanah; Elena Losina; Milton C Weinstein; Xavier Anglaret; Rochelle P Walensky; Heather E Hsu; April Kimmel; Charles Holmes; Jonathan E Kaplan; Kenneth A Freedberg
Journal:  N Engl J Med       Date:  2006-09-14       Impact factor: 91.245

Review 4.  Saving lives efficiently across sectors: the need for a Congressional cost-effectiveness committee.

Authors:  Meagan C Fitzpatrick; Burton H Singer; Peter J Hotez; Alison P Galvani
Journal:  Lancet       Date:  2017-06-29       Impact factor: 79.321

5.  Innovation in the pharmaceutical industry: New estimates of R&D costs.

Authors:  Joseph A DiMasi; Henry G Grabowski; Ronald W Hansen
Journal:  J Health Econ       Date:  2016-02-12       Impact factor: 3.883

Review 6.  Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence.

Authors:  Andrew Creese; Katherine Floyd; Anita Alban; Lorna Guinness
Journal:  Lancet       Date:  2002-05-11       Impact factor: 79.321

Review 7.  Behavioural strategies to reduce HIV transmission: how to make them work better.

Authors:  Thomas J Coates; Linda Richter; Carlos Caceres
Journal:  Lancet       Date:  2008-08-05       Impact factor: 79.321

8.  Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050.

Authors:  Reuben Granich; James G Kahn; Rod Bennett; Charles B Holmes; Navneet Garg; Celicia Serenata; Miriam Lewis Sabin; Carla Makhlouf-Obermeyer; Christina De Filippo Mack; Phoebe Williams; Louisa Jones; Caoimhe Smyth; Kerry A Kutch; Lo Ying-Ru; Marco Vitoria; Yves Souteyrand; Siobhan Crowley; Eline L Korenromp; Brian G Williams
Journal:  PLoS One       Date:  2012-02-13       Impact factor: 3.240

Review 9.  HIV treatment as prevention: considerations in the design, conduct, and analysis of cluster randomized controlled trials of combination HIV prevention.

Authors:  Marie-Claude Boily; Benoît Mâsse; Ramzi Alsallaq; Nancy S Padian; Jeffrey W Eaton; Juan F Vesga; Timothy B Hallett
Journal:  PLoS Med       Date:  2012-07-10       Impact factor: 11.069

Review 10.  HIV prevention cost-effectiveness: a systematic review.

Authors:  Omar Galárraga; M Arantxa Colchero; Richard G Wamai; Stefano M Bertozzi
Journal:  BMC Public Health       Date:  2009-11-18       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.